Navigation Links
Onyx Pharmaceuticals Announces Second Quarter 2011 Financial Results Teleconference and Webcast
Date:7/26/2011

SOUTH SAN FRANCISCO, Calif., July 26, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss second quarter 2011 financial results, as well as provide a general business overview on Wednesday, August 3, 2011, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).  Financial results for the second quarter ended June 30, 2011 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at:
http://www.onyx-pharm.com/investors/event-calendar

or by dialing 847-585-4405 and using the passcode 30130102#.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 30130102# approximately one hour after the teleconference concludes.  The replay will be available through August 17, 2011.

About Onyx Pharmaceuticals, Inc.

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... to whole range ... of Phase II, III and IV Clinical Trials, ... in off-the-shelf and custom supply chain software for the,biopharmaceutical, ... its tcVisualize(TM) 3.0 clinical trial supply simulator. The,latest generation ...
... the,European Society of Cardiology Congress 2007 (ESC Congress 2007) ... clinical benefits compared to a bare metal stent in ... no differences in safety. At five-year follow-up, the ... to be significantly less likely than the patients in ...
Cached Medicine Technology:Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
(Date:8/30/2014)... Daily Gossip reveals in its review a program ... program, who shows a unique formula to get inside a ... says that the program goes beyond mere attraction and actually ... review indicates that the program was created by dating expert ... techniques to make a man feel emotionally addicted. , Learn ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The Plastic ... in New Jersey and even in the U.S. to ... takes inches off of patients’ waists with deep-tissue heating. ... in small sections, Vanquish is more inclusive to target ... Patients lay comfortably under panels about one inch away ...
(Date:8/30/2014)... 30, 2014 Ticket Down ... Tennis Championship tickets in NYC. This popular ... US-OPEN-2014 for all day session, evening session, courtside seats, ... for this prestigious Grand Slam Tournament. , The 2014 ... , US Open Tennis Championship: Men's/Women's 3rd Round - ...
(Date:8/30/2014)... a common problem millions of American cope with every day. While ... for some, it can have a crippling impact on social activity ... mood swings and depression. , Those struggling with acne are ... some cases, that can make the problem even worse. Instead of ... quest for clearer skin can now view acne treatment reviews ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... incretin mimetic claims continue to move forward in U.S. ... issued by AstraZeneca PLC on July 31, 2014, Byetta ... named in 409 product liability claims that allege the ... documents indicate that many of these claims are pending ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3
... of a dedicated pediatric imaging department (with dedicated pediatric computed ... radiation dose delivered to the patient, according to a study ... American College of Radiology. ... outweigh the potential long-term risk of radiation. To minimize the ...
... mammography screening every other year outweigh the potential harms for ... risk of developing breast cancer -- a finding that could ... researchers also found greater harms from screening done with digital ... three national research groups, are published in the May 1 ...
... , MONDAY, April 30 (HealthDay News) -- ... to remove the esophagus of patients with esophageal cancer ... compared to traditional open surgery, a new study finds. ... this less-invasive procedure have much shorter hospital stays and ...
... way deaf and hard-of-hearing students learn are multifaceted: ... skills in both American Sign Language and spoken ... learning strategies. Further understanding of these unique ... particularly in science, technology, engineering and mathematics, the ...
... born every hour addicted to opiate drugs in the United ... In the research published April 30 in the ... that diagnosis of neonatal abstinence syndrome, a drug withdrawal syndrome ... 2009, the estimated number of newborns with the syndrome was ...
... , MONDAY, April 30 (HealthDay News) -- Just ... healthy, a veterinarian says. "Dogs should get exercise at ... each session for small dogs and 30 to 40 minutes ... at the Veterinary Medical Teaching Hospital at Kansas State University ...
Cached Medicine News:Health News:Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose 2Health News:Research examines when benefits of screening mammography outweigh the harms for women in their 40s 2Health News:Research examines when benefits of screening mammography outweigh the harms for women in their 40s 3Health News:Less-Invasive Surgery for Esophageal Cancer Might Be Safer 2Health News:Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students 2Health News:About 1 baby born each hour addicted to opiate drugs in U.S., U-M study shows 2Health News:About 1 baby born each hour addicted to opiate drugs in U.S., U-M study shows 3Health News:Exercise Twice a Day Vital for Your Dog's Health, Expert Says 2
... These award-winning surgical loupes from SheerVision ... users - high resolution optics combined with ... "xx" Ultra-Light loupes weight as little as ... titanium frame, and are available in either ...
... SheerVision manufactures its signature line of ... Sport Frame. These next generation loupes ... ultra-lightweight design, and are multi-coated lens for ... the SV Sport frame offers a stylish, ...
... now the first manufacturer to offer ... the wearer. These next generation loupes ... an ultra-lightweight design, and are multi-coated ... resistance. With SheerVision's proprietary SureFit system ...
... now the first manufacturer to offer ... the wearer. These next generation loupes ... an ultra-lightweight design, and are multi-coated ... resistance. With SheerVision's proprietary SureFit system ...
Medicine Products: